Arcutis Biotherapeutics Inc (NASDAQ: ARQT) flaunted slowness of -4.33% at $13.70, as the Stock market unbolted on Wednesday, before settling in for the price of $14.32 at the close. Taking a more long-term approach, ARQT posted a 52-week range of $6.99-$17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 349.37% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -0.98%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 50.37%. This publicly-traded company’s shares outstanding now amounts to $119.14 million, simultaneously with a float of $104.90 million. The organization now has a market capitalization sitting at $1.71 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.74, while the 200-day Moving Average is $12.04.
Arcutis Biotherapeutics Inc (ARQT) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Arcutis Biotherapeutics Inc industry. Arcutis Biotherapeutics Inc’s current insider ownership accounts for 12.00%, in contrast to 101.29% institutional ownership. According to the most recent insider trade that took place on May 02 ’25, this organization’s insider sold 5,030 shares at the rate of 15.20, making the entire transaction reach 76,453 in total value, affecting insider ownership by 204,399. Preceding that transaction, on May 02 ’25, Company’s insider sold 11,448 for 15.19, making the whole transaction’s value amount to 173,917. This particular insider is now the holder of 913,795 in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Revenue Records
Arcutis Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 50.37% and is forecasted to reach 0.16 in the upcoming year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). It’s Quick Ratio in the last reported quarter now stands at 3.37. The Stock has managed to achieve an average true range (ATR) of 1.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.02.
In the same vein, ARQT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.04, a figure that is expected to reach -0.17 in the next quarter, and analysts are predicting that it will be 0.16 at the market close of one year from today.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Now, what If we examine the latest scores posted by [Arcutis Biotherapeutics Inc, ARQT]. During the last 5-days, its volume was better the volume of 2.37 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 45.39% While, its Average True Range was 1.07.
Raw Stochastic average of Arcutis Biotherapeutics Inc (ARQT) in the period of the previous 100 days is set at 38.82%, which indicates a major fall in contrast to 39.38% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.85% that was lower than 76.73% volatility it exhibited in the past 100-days period.
